Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$231.55
+0.5%
$239.43
$229.40
$287.32
$66.89B0.431.37 million shs706,426 shs
DexCom, Inc. stock logo
DXCM
DexCom
$124.34
-9.9%
$130.98
$74.75
$142.00
$49.24B1.23.05 million shs8.58 million shs
Insulet Co. stock logo
PODD
Insulet
$166.19
+1.2%
$172.00
$125.82
$335.91
$11.64B0.98861,290 shs549,852 shs
ResMed Inc. stock logo
RMD
ResMed
$218.06
+18.9%
$186.31
$132.24
$243.52
$32.07B0.671.06 million shs4.33 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-1.39%-1.15%-4.73%-2.58%-10.85%
DexCom, Inc. stock logo
DXCM
DexCom
+0.10%+2.76%-1.37%+13.16%+10.47%
Insulet Co. stock logo
PODD
Insulet
-1.84%-0.34%-0.82%-16.01%-48.16%
ResMed Inc. stock logo
RMD
ResMed
-0.17%+3.28%-5.53%-3.53%-18.08%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.8984 of 5 stars
2.45.03.34.02.82.52.5
DexCom, Inc. stock logo
DXCM
DexCom
4.9573 of 5 stars
3.55.00.04.72.62.53.1
Insulet Co. stock logo
PODD
Insulet
4.8904 of 5 stars
3.45.00.04.92.50.83.1
ResMed Inc. stock logo
RMD
ResMed
4.584 of 5 stars
2.41.04.24.52.71.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.80
Moderate Buy$280.0020.92% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.6713.93% Upside
Insulet Co. stock logo
PODD
Insulet
2.80
Moderate Buy$243.2146.35% Upside
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$202.80-7.00% Downside

Current Analyst Ratings

Latest DXCM, RMD, PODD, and BDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $160.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$144.00 ➝ $145.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$205.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$227.00 ➝ $238.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$224.00 ➝ $236.00
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
4/3/2024
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$148.00 ➝ $161.00
4/1/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$215.00 ➝ $224.00
3/27/2024
ResMed Inc. stock logo
RMD
ResMed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$215.00
3/12/2024
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$165.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$19.37B3.45$20.03 per share11.56$88.92 per share2.60
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B13.59$1.87 per share66.63$5.35 per share23.24
Insulet Co. stock logo
PODD
Insulet
$1.70B6.86$3.77 per share44.07$10.49 per share15.84
ResMed Inc. stock logo
RMD
ResMed
$4.22B7.60$9.26 per share23.54$28.11 per share7.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.48B$4.2254.8716.171.936.44%13.57%6.56%5/2/2024 (Confirmed)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.3194.9255.762.3714.95%28.31%9.74%7/25/2024 (Estimated)
Insulet Co. stock logo
PODD
Insulet
$206.30M$2.9157.1142.943.0112.16%32.19%7.93%5/9/2024 (Confirmed)
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.0536.0426.342.2519.77%23.86%14.78%8/1/2024 (Estimated)

Latest DXCM, RMD, PODD, and BDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Insulet Co. stock logo
PODD
Insulet
$0.39N/A-$0.39N/AN/AN/A  
5/2/2024N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.96N/A-$2.96N/AN/AN/A  
4/25/2024Q1 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.27$0.32+$0.05$0.28$911.20 million$921.00 million  
4/25/2024Q3 24
ResMed Inc. stock logo
RMD
ResMed
$1.91$2.13+$0.22$2.22$1.17 billion$1.20 billion    
2/22/2024Q4 2023
Insulet Co. stock logo
PODD
Insulet
$0.67$1.40+$0.73$1.36$461.26 million$509.80 million    
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      
2/1/2024Q1 2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.39$2.68+$0.29$4.40$4.73 billion$4.71 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.801.64%+4.77%90.05%52 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.920.88%+5.66%31.74%12 Years

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.56
1.08
0.64
DexCom, Inc. stock logo
DXCM
DexCom
1.18
2.84
2.48
Insulet Co. stock logo
PODD
Insulet
1.86
3.51
2.62
ResMed Inc. stock logo
RMD
ResMed
0.27
3.11
1.89

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Insulet Co. stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.31%
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
Insulet Co. stock logo
PODD
Insulet
0.90%
ResMed Inc. stock logo
RMD
ResMed
1.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
73,000288.90 million288.01 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600396.03 million394.40 millionOptionable
Insulet Co. stock logo
PODD
Insulet
3,00070.02 million69.39 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140147.09 million145.31 millionOptionable

DXCM, RMD, PODD, and BDX Headlines

SourceHeadline
S&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep DevicesS&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep Devices
investopedia.com - April 26 at 5:20 PM
ResMed (NYSE:RMD) Given New $200.00 Price Target at OppenheimerResMed (NYSE:RMD) Given New $200.00 Price Target at Oppenheimer
marketbeat.com - April 26 at 2:44 PM
ResMed Inc. (NYSE:RMD) Stock Position Decreased by Pittenger & Anderson Inc.ResMed Inc. (NYSE:RMD) Stock Position Decreased by Pittenger & Anderson Inc.
marketbeat.com - April 26 at 2:28 PM
ResMed (NYSE:RMD) Price Target Raised to $200.00 at Royal Bank of CanadaResMed (NYSE:RMD) Price Target Raised to $200.00 at Royal Bank of Canada
marketbeat.com - April 26 at 12:41 PM
Why ResMed Stock Is Soaring TodayWhy ResMed Stock Is Soaring Today
fool.com - April 26 at 12:08 PM
ResMed (NYSE:RMD) Shares Gap Up  After Better-Than-Expected EarningsResMed (NYSE:RMD) Shares Gap Up After Better-Than-Expected Earnings
marketbeat.com - April 26 at 10:55 AM
Breaking Down the Key Takeaways from Resmed Inc. (RMD) Quarterly ReportBreaking Down the Key Takeaways from Resmed Inc. (RMD) Quarterly Report
marketbeat.com - April 26 at 10:11 AM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Integer Holdings (ITGR), Resmed (RMD) and PTC Therapeutics (PTCT)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Integer Holdings (ITGR), Resmed (RMD) and PTC Therapeutics (PTCT)
markets.businessinsider.com - April 26 at 10:09 AM
Australian Stocks: ResMed (RMD) Shares Surge on Robust Q3 ResultsAustralian Stocks: ResMed (RMD) Shares Surge on Robust Q3 Results
markets.businessinsider.com - April 26 at 10:09 AM
ResMed Analysts Boost Their Forecasts After Better-Than-Expected EarningsResMed Analysts Boost Their Forecasts After Better-Than-Expected Earnings
benzinga.com - April 26 at 10:09 AM
ResMed (RMD) Q3 Earnings Beat Estimates, Margins ExpandResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
zacks.com - April 26 at 9:41 AM
ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.
barrons.com - April 26 at 8:33 AM
ASX 200 thumped as nagging inflation dashes 2024 rate cut hopes, gold & copper only places to hideASX 200 thumped as nagging inflation dashes 2024 rate cut hopes, gold & copper only places to hide
livewiremarkets.com - April 26 at 5:08 AM
ResMed Inc (RMD) Q3 2024 Earnings Call Transcript Highlights: Strong Financial Performance and ...ResMed Inc (RMD) Q3 2024 Earnings Call Transcript Highlights: Strong Financial Performance and ...
finance.yahoo.com - April 26 at 5:08 AM
ResMed share price jumps 10% on strong quarterly updateResMed share price jumps 10% on strong quarterly update
msn.com - April 26 at 12:07 AM
ResMed Inc. 2024 Q3 - Results - Earnings Call PresentationResMed Inc. 2024 Q3 - Results - Earnings Call Presentation
seekingalpha.com - April 25 at 9:38 PM
RMD Stock Earnings: ResMed Beats EPS, Beats Revenue for Q3 2024RMD Stock Earnings: ResMed Beats EPS, Beats Revenue for Q3 2024
investorplace.com - April 25 at 8:11 PM
Compared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key MetricsCompared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key Metrics
zacks.com - April 25 at 7:31 PM
ResMed: Fiscal Q3 Earnings SnapshotResMed: Fiscal Q3 Earnings Snapshot
timesunion.com - April 25 at 7:07 PM
Resmed Inc Q3 Profit Increases, beats estimatesResmed Inc Q3 Profit Increases, beats estimates
markets.businessinsider.com - April 25 at 7:07 PM
ResMed sees increased sleep device demand, stock rises on Q3 beatsResMed sees increased sleep device demand, stock rises on Q3 beats
massdevice.com - April 25 at 7:07 PM
ResMed Inc (RMD) Q3 Fiscal 2024 Earnings: Surpasses Analyst Expectations with Strong GrowthResMed Inc (RMD) Q3 Fiscal 2024 Earnings: Surpasses Analyst Expectations with Strong Growth
finance.yahoo.com - April 25 at 7:07 PM
ResMed (NYSE:RMD) Releases Quarterly  Earnings Results, Beats Estimates By $0.22 EPSResMed (NYSE:RMD) Releases Quarterly Earnings Results, Beats Estimates By $0.22 EPS
marketbeat.com - April 25 at 7:01 PM
ResMed (RMD) Q3 Earnings and Revenues Surpass EstimatesResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
zacks.com - April 25 at 6:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Becton, Dickinson and Company logo

Becton, Dickinson and Company

NYSE:BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Insulet logo

Insulet

NASDAQ:PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.